nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—ABCB1—hematologic cancer	0.0786	1	CbGaD
Paroxetine—CYP2B6—Thiotepa—hematologic cancer	0.0311	0.0649	CbGbCtD
Paroxetine—CYP2C9—Bexarotene—hematologic cancer	0.0199	0.0414	CbGbCtD
Paroxetine—ABCB1—Lenalidomide—hematologic cancer	0.0193	0.0401	CbGbCtD
Paroxetine—CYP2B6—Ifosfamide—hematologic cancer	0.0177	0.0368	CbGbCtD
Paroxetine—CYP2C8—Bortezomib—hematologic cancer	0.0174	0.0363	CbGbCtD
Paroxetine—CYP2D6—Lomustine—hematologic cancer	0.0169	0.0352	CbGbCtD
Paroxetine—CYP2C9—Idarubicin—hematologic cancer	0.0165	0.0343	CbGbCtD
Paroxetine—CYP2B6—Nilotinib—hematologic cancer	0.0153	0.0319	CbGbCtD
Paroxetine—CYP2D6—Idarubicin—hematologic cancer	0.015	0.0313	CbGbCtD
Paroxetine—CYP2C8—Ifosfamide—hematologic cancer	0.0134	0.0279	CbGbCtD
Paroxetine—CYP2D6—Hydroxyurea—hematologic cancer	0.0128	0.0266	CbGbCtD
Paroxetine—CYP2C9—Bortezomib—hematologic cancer	0.0122	0.0253	CbGbCtD
Paroxetine—CYP2C8—Nilotinib—hematologic cancer	0.0116	0.0242	CbGbCtD
Paroxetine—ABCB1—Daunorubicin—hematologic cancer	0.0113	0.0235	CbGbCtD
Paroxetine—CYP2D6—Bortezomib—hematologic cancer	0.0111	0.0232	CbGbCtD
Paroxetine—ABCB1—Alitretinoin—hematologic cancer	0.0111	0.0231	CbGbCtD
Paroxetine—CYP2C9—Thalidomide—hematologic cancer	0.0106	0.0221	CbGbCtD
Paroxetine—CYP2B6—Irinotecan—hematologic cancer	0.0105	0.022	CbGbCtD
Paroxetine—CYP2C9—Teniposide—hematologic cancer	0.0101	0.0211	CbGbCtD
Paroxetine—CYP2C9—Ifosfamide—hematologic cancer	0.00933	0.0194	CbGbCtD
Paroxetine—CYP2C9—Imatinib—hematologic cancer	0.00892	0.0186	CbGbCtD
Paroxetine—ABCB1—Imatinib—hematologic cancer	0.00865	0.018	CbGbCtD
Paroxetine—CYP2B6—Cisplatin—hematologic cancer	0.00859	0.0179	CbGbCtD
Paroxetine—CYP2D6—Imatinib—hematologic cancer	0.00815	0.017	CbGbCtD
Paroxetine—CYP2C9—Nilotinib—hematologic cancer	0.0081	0.0169	CbGbCtD
Paroxetine—ABCB1—Nilotinib—hematologic cancer	0.00786	0.0164	CbGbCtD
Paroxetine—ABCB1—Vinorelbine—hematologic cancer	0.0078	0.0162	CbGbCtD
Paroxetine—CYP2D6—Nilotinib—hematologic cancer	0.00741	0.0154	CbGbCtD
Paroxetine—CYP2D6—Vinorelbine—hematologic cancer	0.00735	0.0153	CbGbCtD
Paroxetine—ABCB1—Dasatinib—hematologic cancer	0.00695	0.0145	CbGbCtD
Paroxetine—CYP2B6—Dexamethasone—hematologic cancer	0.00694	0.0145	CbGbCtD
Paroxetine—ABCB1—Mitoxantrone—hematologic cancer	0.00687	0.0143	CbGbCtD
Paroxetine—CYP2C8—Etoposide—hematologic cancer	0.0064	0.0133	CbGbCtD
Paroxetine—ABCB1—Betamethasone—hematologic cancer	0.00612	0.0127	CbGbCtD
Paroxetine—ABCB1—Gemcitabine—hematologic cancer	0.00606	0.0126	CbGbCtD
Paroxetine—ABCB1—Prednisolone—hematologic cancer	0.00604	0.0126	CbGbCtD
Paroxetine—CYP2B6—Doxorubicin—hematologic cancer	0.00576	0.012	CbGbCtD
Paroxetine—ABCB1—Prednisone—hematologic cancer	0.0057	0.0119	CbGbCtD
Paroxetine—ABCB1—Irinotecan—hematologic cancer	0.00541	0.0113	CbGbCtD
Paroxetine—CYP2C8—Dexamethasone—hematologic cancer	0.00526	0.011	CbGbCtD
Paroxetine—ABCB1—Vinblastine—hematologic cancer	0.00481	0.01	CbGbCtD
Paroxetine—ABCB1—Vincristine—hematologic cancer	0.00472	0.00984	CbGbCtD
Paroxetine—CYP2C9—Cisplatin—hematologic cancer	0.00454	0.00946	CbGbCtD
Paroxetine—CYP2D6—Vinblastine—hematologic cancer	0.00453	0.00943	CbGbCtD
Paroxetine—ABCB1—Cisplatin—hematologic cancer	0.00441	0.00918	CbGbCtD
Paroxetine—ABCB1—Etoposide—hematologic cancer	0.00433	0.00902	CbGbCtD
Paroxetine—CYP2C9—Dexamethasone—hematologic cancer	0.00367	0.00764	CbGbCtD
Paroxetine—ABCB1—Dexamethasone—hematologic cancer	0.00356	0.00741	CbGbCtD
Paroxetine—CYP2D6—Dexamethasone—hematologic cancer	0.00335	0.00698	CbGbCtD
Paroxetine—ABCB1—Doxorubicin—hematologic cancer	0.00295	0.00615	CbGbCtD
Paroxetine—ABCB1—Methotrexate—hematologic cancer	0.00286	0.00596	CbGbCtD
Paroxetine—CYP2D6—Doxorubicin—hematologic cancer	0.00278	0.00579	CbGbCtD
Paroxetine—TACR1—hematopoietic system—hematologic cancer	0.00209	0.0861	CbGeAlD
Paroxetine—TACR1—blood—hematologic cancer	0.00138	0.0571	CbGeAlD
Paroxetine—TACR1—lung—hematologic cancer	0.00121	0.05	CbGeAlD
Paroxetine—TACR1—testis—hematologic cancer	0.00114	0.0472	CbGeAlD
Paroxetine—CHRM4—testis—hematologic cancer	0.00108	0.0444	CbGeAlD
Paroxetine—SLC6A3—hematopoietic system—hematologic cancer	0.00105	0.0433	CbGeAlD
Paroxetine—SLC6A4—hematopoietic system—hematologic cancer	0.000962	0.0397	CbGeAlD
Paroxetine—TACR1—lymph node—hematologic cancer	0.000829	0.0342	CbGeAlD
Paroxetine—CYP2C8—hematopoietic system—hematologic cancer	0.000696	0.0287	CbGeAlD
Paroxetine—SLC6A2—gonad—hematologic cancer	0.000644	0.0266	CbGeAlD
Paroxetine—SLC6A4—blood—hematologic cancer	0.000638	0.0263	CbGeAlD
Paroxetine—CYP2B6—hematopoietic system—hematologic cancer	0.000624	0.0258	CbGeAlD
Paroxetine—CYP2C9—hematopoietic system—hematologic cancer	0.000618	0.0255	CbGeAlD
Paroxetine—SLC6A3—lung—hematologic cancer	0.00061	0.0252	CbGeAlD
Paroxetine—SLC6A3—testis—hematologic cancer	0.000576	0.0237	CbGeAlD
Paroxetine—SLC6A4—lung—hematologic cancer	0.000559	0.0231	CbGeAlD
Paroxetine—CHRM1—lung—hematologic cancer	0.000557	0.023	CbGeAlD
Paroxetine—HTR2A—hematopoietic system—hematologic cancer	0.000509	0.021	CbGeAlD
Paroxetine—SLC6A2—lung—hematologic cancer	0.000492	0.0203	CbGeAlD
Paroxetine—CYP2B6—gonad—hematologic cancer	0.000475	0.0196	CbGeAlD
Paroxetine—CHRM3—testis—hematologic cancer	0.00047	0.0194	CbGeAlD
Paroxetine—SLC6A2—testis—hematologic cancer	0.000464	0.0192	CbGeAlD
Paroxetine—CYP2D6—hematopoietic system—hematologic cancer	0.000464	0.0191	CbGeAlD
Paroxetine—CYP2C8—blood—hematologic cancer	0.000461	0.019	CbGeAlD
Paroxetine—CYP2B6—blood—hematologic cancer	0.000414	0.0171	CbGeAlD
Paroxetine—CYP2C9—blood—hematologic cancer	0.00041	0.0169	CbGeAlD
Paroxetine—HTR2A—gonad—hematologic cancer	0.000387	0.016	CbGeAlD
Paroxetine—CYP2C8—testis—hematologic cancer	0.000381	0.0157	CbGeAlD
Paroxetine—CYP2B6—lung—hematologic cancer	0.000363	0.015	CbGeAlD
Paroxetine—CYP2B6—testis—hematologic cancer	0.000342	0.0141	CbGeAlD
Paroxetine—HTR2A—blood—hematologic cancer	0.000337	0.0139	CbGeAlD
Paroxetine—SLC6A2—lymph node—hematologic cancer	0.000337	0.0139	CbGeAlD
Paroxetine—ABCB1—hematopoietic system—hematologic cancer	0.000334	0.0138	CbGeAlD
Paroxetine—CYP2D6—blood—hematologic cancer	0.000307	0.0127	CbGeAlD
Paroxetine—HTR2A—lung—hematologic cancer	0.000296	0.0122	CbGeAlD
Paroxetine—HTR2A—testis—hematologic cancer	0.000279	0.0115	CbGeAlD
Paroxetine—CYP2D6—testis—hematologic cancer	0.000254	0.0105	CbGeAlD
Paroxetine—ABCB1—gonad—hematologic cancer	0.000254	0.0105	CbGeAlD
Paroxetine—ABCB1—blood—hematologic cancer	0.000221	0.00912	CbGeAlD
Paroxetine—ABCB1—bone marrow—hematologic cancer	0.000214	0.00882	CbGeAlD
Paroxetine—ABCB1—lung—hematologic cancer	0.000194	0.00799	CbGeAlD
Paroxetine—ABCB1—testis—hematologic cancer	0.000183	0.00754	CbGeAlD
Paroxetine—ABCB1—lymph node—hematologic cancer	0.000133	0.00547	CbGeAlD
Paroxetine—Feeling abnormal—Dexamethasone—hematologic cancer	1.14e-05	3.53e-05	CcSEcCtD
Paroxetine—Cardiac disorder—Doxorubicin—hematologic cancer	1.14e-05	3.53e-05	CcSEcCtD
Paroxetine—Flushing—Doxorubicin—hematologic cancer	1.14e-05	3.53e-05	CcSEcCtD
Paroxetine—Flatulence—Epirubicin—hematologic cancer	1.14e-05	3.52e-05	CcSEcCtD
Paroxetine—Tension—Epirubicin—hematologic cancer	1.13e-05	3.51e-05	CcSEcCtD
Paroxetine—Gastrointestinal pain—Dexamethasone—hematologic cancer	1.13e-05	3.5e-05	CcSEcCtD
Paroxetine—Gastrointestinal pain—Betamethasone—hematologic cancer	1.13e-05	3.5e-05	CcSEcCtD
Paroxetine—Dysgeusia—Epirubicin—hematologic cancer	1.13e-05	3.5e-05	CcSEcCtD
Paroxetine—Hypersensitivity—Triamcinolone—hematologic cancer	1.13e-05	3.48e-05	CcSEcCtD
Paroxetine—Nervousness—Epirubicin—hematologic cancer	1.12e-05	3.47e-05	CcSEcCtD
Paroxetine—Back pain—Epirubicin—hematologic cancer	1.12e-05	3.46e-05	CcSEcCtD
Paroxetine—Angiopathy—Doxorubicin—hematologic cancer	1.12e-05	3.45e-05	CcSEcCtD
Paroxetine—Malaise—Methotrexate—hematologic cancer	1.11e-05	3.45e-05	CcSEcCtD
Paroxetine—Dizziness—Etoposide—hematologic cancer	1.11e-05	3.44e-05	CcSEcCtD
Paroxetine—Muscle spasms—Epirubicin—hematologic cancer	1.11e-05	3.44e-05	CcSEcCtD
Paroxetine—Immune system disorder—Doxorubicin—hematologic cancer	1.11e-05	3.43e-05	CcSEcCtD
Paroxetine—Vertigo—Methotrexate—hematologic cancer	1.11e-05	3.43e-05	CcSEcCtD
Paroxetine—Mediastinal disorder—Doxorubicin—hematologic cancer	1.11e-05	3.43e-05	CcSEcCtD
Paroxetine—Leukopenia—Methotrexate—hematologic cancer	1.11e-05	3.42e-05	CcSEcCtD
Paroxetine—Chills—Doxorubicin—hematologic cancer	1.1e-05	3.41e-05	CcSEcCtD
Paroxetine—Urticaria—Betamethasone—hematologic cancer	1.1e-05	3.4e-05	CcSEcCtD
Paroxetine—Urticaria—Dexamethasone—hematologic cancer	1.1e-05	3.4e-05	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Prednisone—hematologic cancer	1.1e-05	3.4e-05	CcSEcCtD
Paroxetine—Dizziness—Prednisolone—hematologic cancer	1.1e-05	3.4e-05	CcSEcCtD
Paroxetine—Arrhythmia—Doxorubicin—hematologic cancer	1.1e-05	3.4e-05	CcSEcCtD
Paroxetine—Asthenia—Triamcinolone—hematologic cancer	1.1e-05	3.39e-05	CcSEcCtD
Paroxetine—Abdominal pain—Betamethasone—hematologic cancer	1.1e-05	3.39e-05	CcSEcCtD
Paroxetine—Body temperature increased—Dexamethasone—hematologic cancer	1.1e-05	3.39e-05	CcSEcCtD
Paroxetine—Abdominal pain—Dexamethasone—hematologic cancer	1.1e-05	3.39e-05	CcSEcCtD
Paroxetine—Body temperature increased—Betamethasone—hematologic cancer	1.1e-05	3.39e-05	CcSEcCtD
Paroxetine—Nausea—Cisplatin—hematologic cancer	1.09e-05	3.38e-05	CcSEcCtD
Paroxetine—Insomnia—Prednisone—hematologic cancer	1.09e-05	3.38e-05	CcSEcCtD
Paroxetine—Vision blurred—Epirubicin—hematologic cancer	1.09e-05	3.37e-05	CcSEcCtD
Paroxetine—Alopecia—Doxorubicin—hematologic cancer	1.09e-05	3.36e-05	CcSEcCtD
Paroxetine—Paraesthesia—Prednisone—hematologic cancer	1.08e-05	3.35e-05	CcSEcCtD
Paroxetine—Pruritus—Triamcinolone—hematologic cancer	1.08e-05	3.34e-05	CcSEcCtD
Paroxetine—Cough—Methotrexate—hematologic cancer	1.08e-05	3.33e-05	CcSEcCtD
Paroxetine—Mental disorder—Doxorubicin—hematologic cancer	1.08e-05	3.33e-05	CcSEcCtD
Paroxetine—Ill-defined disorder—Epirubicin—hematologic cancer	1.07e-05	3.32e-05	CcSEcCtD
Paroxetine—Convulsion—Methotrexate—hematologic cancer	1.07e-05	3.31e-05	CcSEcCtD
Paroxetine—Vomiting—Etoposide—hematologic cancer	1.07e-05	3.31e-05	CcSEcCtD
Paroxetine—Erythema—Doxorubicin—hematologic cancer	1.07e-05	3.31e-05	CcSEcCtD
Paroxetine—Malnutrition—Doxorubicin—hematologic cancer	1.07e-05	3.31e-05	CcSEcCtD
Paroxetine—Anaemia—Epirubicin—hematologic cancer	1.07e-05	3.31e-05	CcSEcCtD
Paroxetine—Agitation—Epirubicin—hematologic cancer	1.06e-05	3.29e-05	CcSEcCtD
Paroxetine—Dyspepsia—Prednisone—hematologic cancer	1.06e-05	3.29e-05	CcSEcCtD
Paroxetine—Rash—Etoposide—hematologic cancer	1.06e-05	3.28e-05	CcSEcCtD
Paroxetine—Dermatitis—Etoposide—hematologic cancer	1.06e-05	3.28e-05	CcSEcCtD
Paroxetine—Headache—Etoposide—hematologic cancer	1.05e-05	3.26e-05	CcSEcCtD
Paroxetine—Flatulence—Doxorubicin—hematologic cancer	1.05e-05	3.26e-05	CcSEcCtD
Paroxetine—Chest pain—Methotrexate—hematologic cancer	1.05e-05	3.25e-05	CcSEcCtD
Paroxetine—Arthralgia—Methotrexate—hematologic cancer	1.05e-05	3.25e-05	CcSEcCtD
Paroxetine—Myalgia—Methotrexate—hematologic cancer	1.05e-05	3.25e-05	CcSEcCtD
Paroxetine—Tension—Doxorubicin—hematologic cancer	1.05e-05	3.25e-05	CcSEcCtD
Paroxetine—Decreased appetite—Prednisone—hematologic cancer	1.05e-05	3.24e-05	CcSEcCtD
Paroxetine—Dysgeusia—Doxorubicin—hematologic cancer	1.05e-05	3.24e-05	CcSEcCtD
Paroxetine—Rash—Prednisolone—hematologic cancer	1.05e-05	3.24e-05	CcSEcCtD
Paroxetine—Dermatitis—Prednisolone—hematologic cancer	1.05e-05	3.24e-05	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	1.04e-05	3.23e-05	CcSEcCtD
Paroxetine—Malaise—Epirubicin—hematologic cancer	1.04e-05	3.23e-05	CcSEcCtD
Paroxetine—Fatigue—Prednisone—hematologic cancer	1.04e-05	3.22e-05	CcSEcCtD
Paroxetine—Headache—Prednisolone—hematologic cancer	1.04e-05	3.22e-05	CcSEcCtD
Paroxetine—Discomfort—Methotrexate—hematologic cancer	1.04e-05	3.21e-05	CcSEcCtD
Paroxetine—Nervousness—Doxorubicin—hematologic cancer	1.04e-05	3.21e-05	CcSEcCtD
Paroxetine—Vertigo—Epirubicin—hematologic cancer	1.04e-05	3.21e-05	CcSEcCtD
Paroxetine—Syncope—Epirubicin—hematologic cancer	1.04e-05	3.21e-05	CcSEcCtD
Paroxetine—Leukopenia—Epirubicin—hematologic cancer	1.04e-05	3.2e-05	CcSEcCtD
Paroxetine—Back pain—Doxorubicin—hematologic cancer	1.04e-05	3.2e-05	CcSEcCtD
Paroxetine—Constipation—Prednisone—hematologic cancer	1.03e-05	3.19e-05	CcSEcCtD
Paroxetine—Muscle spasms—Doxorubicin—hematologic cancer	1.03e-05	3.18e-05	CcSEcCtD
Paroxetine—Palpitations—Epirubicin—hematologic cancer	1.02e-05	3.16e-05	CcSEcCtD
Paroxetine—Confusional state—Methotrexate—hematologic cancer	1.02e-05	3.14e-05	CcSEcCtD
Paroxetine—Loss of consciousness—Epirubicin—hematologic cancer	1.02e-05	3.14e-05	CcSEcCtD
Paroxetine—Dizziness—Triamcinolone—hematologic cancer	1.01e-05	3.12e-05	CcSEcCtD
Paroxetine—Cough—Epirubicin—hematologic cancer	1.01e-05	3.12e-05	CcSEcCtD
Paroxetine—Anaphylactic shock—Methotrexate—hematologic cancer	1.01e-05	3.12e-05	CcSEcCtD
Paroxetine—Vision blurred—Doxorubicin—hematologic cancer	1.01e-05	3.12e-05	CcSEcCtD
Paroxetine—Convulsion—Epirubicin—hematologic cancer	1e-05	3.1e-05	CcSEcCtD
Paroxetine—Infection—Methotrexate—hematologic cancer	1e-05	3.1e-05	CcSEcCtD
Paroxetine—Nausea—Etoposide—hematologic cancer	1e-05	3.09e-05	CcSEcCtD
Paroxetine—Hypertension—Epirubicin—hematologic cancer	9.99e-06	3.09e-05	CcSEcCtD
Paroxetine—Feeling abnormal—Prednisone—hematologic cancer	9.95e-06	3.08e-05	CcSEcCtD
Paroxetine—Asthenia—Betamethasone—hematologic cancer	9.94e-06	3.07e-05	CcSEcCtD
Paroxetine—Asthenia—Dexamethasone—hematologic cancer	9.94e-06	3.07e-05	CcSEcCtD
Paroxetine—Ill-defined disorder—Doxorubicin—hematologic cancer	9.93e-06	3.07e-05	CcSEcCtD
Paroxetine—Nervous system disorder—Methotrexate—hematologic cancer	9.89e-06	3.06e-05	CcSEcCtD
Paroxetine—Anaemia—Doxorubicin—hematologic cancer	9.89e-06	3.06e-05	CcSEcCtD
Paroxetine—Thrombocytopenia—Methotrexate—hematologic cancer	9.88e-06	3.05e-05	CcSEcCtD
Paroxetine—Gastrointestinal pain—Prednisone—hematologic cancer	9.87e-06	3.05e-05	CcSEcCtD
Paroxetine—Nausea—Prednisolone—hematologic cancer	9.87e-06	3.05e-05	CcSEcCtD
Paroxetine—Myalgia—Epirubicin—hematologic cancer	9.85e-06	3.04e-05	CcSEcCtD
Paroxetine—Chest pain—Epirubicin—hematologic cancer	9.85e-06	3.04e-05	CcSEcCtD
Paroxetine—Arthralgia—Epirubicin—hematologic cancer	9.85e-06	3.04e-05	CcSEcCtD
Paroxetine—Agitation—Doxorubicin—hematologic cancer	9.83e-06	3.04e-05	CcSEcCtD
Paroxetine—Anxiety—Epirubicin—hematologic cancer	9.81e-06	3.03e-05	CcSEcCtD
Paroxetine—Pruritus—Dexamethasone—hematologic cancer	9.8e-06	3.03e-05	CcSEcCtD
Paroxetine—Pruritus—Betamethasone—hematologic cancer	9.8e-06	3.03e-05	CcSEcCtD
Paroxetine—Skin disorder—Methotrexate—hematologic cancer	9.8e-06	3.03e-05	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	9.78e-06	3.02e-05	CcSEcCtD
Paroxetine—Hyperhidrosis—Methotrexate—hematologic cancer	9.75e-06	3.02e-05	CcSEcCtD
Paroxetine—Discomfort—Epirubicin—hematologic cancer	9.73e-06	3.01e-05	CcSEcCtD
Paroxetine—Vomiting—Triamcinolone—hematologic cancer	9.71e-06	3e-05	CcSEcCtD
Paroxetine—Malaise—Doxorubicin—hematologic cancer	9.65e-06	2.98e-05	CcSEcCtD
Paroxetine—Rash—Triamcinolone—hematologic cancer	9.63e-06	2.98e-05	CcSEcCtD
Paroxetine—Dry mouth—Epirubicin—hematologic cancer	9.63e-06	2.98e-05	CcSEcCtD
Paroxetine—Dermatitis—Triamcinolone—hematologic cancer	9.62e-06	2.98e-05	CcSEcCtD
Paroxetine—Vertigo—Doxorubicin—hematologic cancer	9.61e-06	2.97e-05	CcSEcCtD
Paroxetine—Syncope—Doxorubicin—hematologic cancer	9.6e-06	2.97e-05	CcSEcCtD
Paroxetine—Urticaria—Prednisone—hematologic cancer	9.59e-06	2.96e-05	CcSEcCtD
Paroxetine—Leukopenia—Doxorubicin—hematologic cancer	9.58e-06	2.96e-05	CcSEcCtD
Paroxetine—Headache—Triamcinolone—hematologic cancer	9.57e-06	2.96e-05	CcSEcCtD
Paroxetine—Abdominal pain—Prednisone—hematologic cancer	9.54e-06	2.95e-05	CcSEcCtD
Paroxetine—Body temperature increased—Prednisone—hematologic cancer	9.54e-06	2.95e-05	CcSEcCtD
Paroxetine—Confusional state—Epirubicin—hematologic cancer	9.52e-06	2.94e-05	CcSEcCtD
Paroxetine—Diarrhoea—Betamethasone—hematologic cancer	9.48e-06	2.93e-05	CcSEcCtD
Paroxetine—Diarrhoea—Dexamethasone—hematologic cancer	9.48e-06	2.93e-05	CcSEcCtD
Paroxetine—Palpitations—Doxorubicin—hematologic cancer	9.46e-06	2.92e-05	CcSEcCtD
Paroxetine—Oedema—Epirubicin—hematologic cancer	9.44e-06	2.92e-05	CcSEcCtD
Paroxetine—Anaphylactic shock—Epirubicin—hematologic cancer	9.44e-06	2.92e-05	CcSEcCtD
Paroxetine—Hypotension—Methotrexate—hematologic cancer	9.42e-06	2.91e-05	CcSEcCtD
Paroxetine—Loss of consciousness—Doxorubicin—hematologic cancer	9.41e-06	2.91e-05	CcSEcCtD
Paroxetine—Infection—Epirubicin—hematologic cancer	9.38e-06	2.9e-05	CcSEcCtD
Paroxetine—Cough—Doxorubicin—hematologic cancer	9.34e-06	2.89e-05	CcSEcCtD
Paroxetine—Shock—Epirubicin—hematologic cancer	9.29e-06	2.87e-05	CcSEcCtD
Paroxetine—Convulsion—Doxorubicin—hematologic cancer	9.27e-06	2.87e-05	CcSEcCtD
Paroxetine—Nervous system disorder—Epirubicin—hematologic cancer	9.26e-06	2.86e-05	CcSEcCtD
Paroxetine—Thrombocytopenia—Epirubicin—hematologic cancer	9.24e-06	2.86e-05	CcSEcCtD
Paroxetine—Hypertension—Doxorubicin—hematologic cancer	9.24e-06	2.86e-05	CcSEcCtD
Paroxetine—Tachycardia—Epirubicin—hematologic cancer	9.21e-06	2.85e-05	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Methotrexate—hematologic cancer	9.19e-06	2.84e-05	CcSEcCtD
Paroxetine—Skin disorder—Epirubicin—hematologic cancer	9.17e-06	2.84e-05	CcSEcCtD
Paroxetine—Dizziness—Betamethasone—hematologic cancer	9.16e-06	2.83e-05	CcSEcCtD
Paroxetine—Dizziness—Dexamethasone—hematologic cancer	9.16e-06	2.83e-05	CcSEcCtD
Paroxetine—Hyperhidrosis—Epirubicin—hematologic cancer	9.12e-06	2.82e-05	CcSEcCtD
Paroxetine—Insomnia—Methotrexate—hematologic cancer	9.12e-06	2.82e-05	CcSEcCtD
Paroxetine—Arthralgia—Doxorubicin—hematologic cancer	9.11e-06	2.82e-05	CcSEcCtD
Paroxetine—Chest pain—Doxorubicin—hematologic cancer	9.11e-06	2.82e-05	CcSEcCtD
Paroxetine—Myalgia—Doxorubicin—hematologic cancer	9.11e-06	2.82e-05	CcSEcCtD
Paroxetine—Anxiety—Doxorubicin—hematologic cancer	9.08e-06	2.81e-05	CcSEcCtD
Paroxetine—Nausea—Triamcinolone—hematologic cancer	9.07e-06	2.81e-05	CcSEcCtD
Paroxetine—Paraesthesia—Methotrexate—hematologic cancer	9.06e-06	2.8e-05	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	9.05e-06	2.8e-05	CcSEcCtD
Paroxetine—Discomfort—Doxorubicin—hematologic cancer	9e-06	2.78e-05	CcSEcCtD
Paroxetine—Dyspnoea—Methotrexate—hematologic cancer	8.99e-06	2.78e-05	CcSEcCtD
Paroxetine—Somnolence—Methotrexate—hematologic cancer	8.97e-06	2.77e-05	CcSEcCtD
Paroxetine—Dry mouth—Doxorubicin—hematologic cancer	8.91e-06	2.76e-05	CcSEcCtD
Paroxetine—Hypersensitivity—Prednisone—hematologic cancer	8.89e-06	2.75e-05	CcSEcCtD
Paroxetine—Dyspepsia—Methotrexate—hematologic cancer	8.88e-06	2.75e-05	CcSEcCtD
Paroxetine—Hypotension—Epirubicin—hematologic cancer	8.82e-06	2.73e-05	CcSEcCtD
Paroxetine—Vomiting—Betamethasone—hematologic cancer	8.81e-06	2.72e-05	CcSEcCtD
Paroxetine—Vomiting—Dexamethasone—hematologic cancer	8.81e-06	2.72e-05	CcSEcCtD
Paroxetine—Confusional state—Doxorubicin—hematologic cancer	8.81e-06	2.72e-05	CcSEcCtD
Paroxetine—Decreased appetite—Methotrexate—hematologic cancer	8.77e-06	2.71e-05	CcSEcCtD
Paroxetine—Rash—Dexamethasone—hematologic cancer	8.74e-06	2.7e-05	CcSEcCtD
Paroxetine—Rash—Betamethasone—hematologic cancer	8.74e-06	2.7e-05	CcSEcCtD
Paroxetine—Oedema—Doxorubicin—hematologic cancer	8.73e-06	2.7e-05	CcSEcCtD
Paroxetine—Anaphylactic shock—Doxorubicin—hematologic cancer	8.73e-06	2.7e-05	CcSEcCtD
Paroxetine—Dermatitis—Dexamethasone—hematologic cancer	8.73e-06	2.7e-05	CcSEcCtD
Paroxetine—Dermatitis—Betamethasone—hematologic cancer	8.73e-06	2.7e-05	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Methotrexate—hematologic cancer	8.71e-06	2.69e-05	CcSEcCtD
Paroxetine—Fatigue—Methotrexate—hematologic cancer	8.7e-06	2.69e-05	CcSEcCtD
Paroxetine—Headache—Betamethasone—hematologic cancer	8.68e-06	2.68e-05	CcSEcCtD
Paroxetine—Headache—Dexamethasone—hematologic cancer	8.68e-06	2.68e-05	CcSEcCtD
Paroxetine—Infection—Doxorubicin—hematologic cancer	8.68e-06	2.68e-05	CcSEcCtD
Paroxetine—Asthenia—Prednisone—hematologic cancer	8.66e-06	2.68e-05	CcSEcCtD
Paroxetine—Pain—Methotrexate—hematologic cancer	8.63e-06	2.67e-05	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Epirubicin—hematologic cancer	8.6e-06	2.66e-05	CcSEcCtD
Paroxetine—Shock—Doxorubicin—hematologic cancer	8.59e-06	2.66e-05	CcSEcCtD
Paroxetine—Nervous system disorder—Doxorubicin—hematologic cancer	8.56e-06	2.65e-05	CcSEcCtD
Paroxetine—Thrombocytopenia—Doxorubicin—hematologic cancer	8.55e-06	2.64e-05	CcSEcCtD
Paroxetine—Pruritus—Prednisone—hematologic cancer	8.54e-06	2.64e-05	CcSEcCtD
Paroxetine—Insomnia—Epirubicin—hematologic cancer	8.54e-06	2.64e-05	CcSEcCtD
Paroxetine—Tachycardia—Doxorubicin—hematologic cancer	8.52e-06	2.64e-05	CcSEcCtD
Paroxetine—Skin disorder—Doxorubicin—hematologic cancer	8.48e-06	2.62e-05	CcSEcCtD
Paroxetine—Paraesthesia—Epirubicin—hematologic cancer	8.48e-06	2.62e-05	CcSEcCtD
Paroxetine—Hyperhidrosis—Doxorubicin—hematologic cancer	8.44e-06	2.61e-05	CcSEcCtD
Paroxetine—Dyspnoea—Epirubicin—hematologic cancer	8.42e-06	2.6e-05	CcSEcCtD
Paroxetine—Somnolence—Epirubicin—hematologic cancer	8.39e-06	2.59e-05	CcSEcCtD
Paroxetine—Feeling abnormal—Methotrexate—hematologic cancer	8.31e-06	2.57e-05	CcSEcCtD
Paroxetine—Dyspepsia—Epirubicin—hematologic cancer	8.31e-06	2.57e-05	CcSEcCtD
Paroxetine—Diarrhoea—Prednisone—hematologic cancer	8.26e-06	2.55e-05	CcSEcCtD
Paroxetine—Gastrointestinal pain—Methotrexate—hematologic cancer	8.25e-06	2.55e-05	CcSEcCtD
Paroxetine—Nausea—Dexamethasone—hematologic cancer	8.23e-06	2.55e-05	CcSEcCtD
Paroxetine—Nausea—Betamethasone—hematologic cancer	8.23e-06	2.55e-05	CcSEcCtD
Paroxetine—Decreased appetite—Epirubicin—hematologic cancer	8.21e-06	2.54e-05	CcSEcCtD
Paroxetine—Hypotension—Doxorubicin—hematologic cancer	8.16e-06	2.52e-05	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Epirubicin—hematologic cancer	8.15e-06	2.52e-05	CcSEcCtD
Paroxetine—Fatigue—Epirubicin—hematologic cancer	8.14e-06	2.52e-05	CcSEcCtD
Paroxetine—Pain—Epirubicin—hematologic cancer	8.07e-06	2.5e-05	CcSEcCtD
Paroxetine—Constipation—Epirubicin—hematologic cancer	8.07e-06	2.5e-05	CcSEcCtD
Paroxetine—Urticaria—Methotrexate—hematologic cancer	8.01e-06	2.48e-05	CcSEcCtD
Paroxetine—Dizziness—Prednisone—hematologic cancer	7.98e-06	2.47e-05	CcSEcCtD
Paroxetine—Abdominal pain—Methotrexate—hematologic cancer	7.97e-06	2.47e-05	CcSEcCtD
Paroxetine—Body temperature increased—Methotrexate—hematologic cancer	7.97e-06	2.47e-05	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	7.96e-06	2.46e-05	CcSEcCtD
Paroxetine—Insomnia—Doxorubicin—hematologic cancer	7.9e-06	2.44e-05	CcSEcCtD
Paroxetine—Paraesthesia—Doxorubicin—hematologic cancer	7.84e-06	2.43e-05	CcSEcCtD
Paroxetine—Dyspnoea—Doxorubicin—hematologic cancer	7.79e-06	2.41e-05	CcSEcCtD
Paroxetine—Feeling abnormal—Epirubicin—hematologic cancer	7.78e-06	2.41e-05	CcSEcCtD
Paroxetine—Somnolence—Doxorubicin—hematologic cancer	7.76e-06	2.4e-05	CcSEcCtD
Paroxetine—Gastrointestinal pain—Epirubicin—hematologic cancer	7.72e-06	2.39e-05	CcSEcCtD
Paroxetine—Dyspepsia—Doxorubicin—hematologic cancer	7.69e-06	2.38e-05	CcSEcCtD
Paroxetine—Vomiting—Prednisone—hematologic cancer	7.67e-06	2.37e-05	CcSEcCtD
Paroxetine—Rash—Prednisone—hematologic cancer	7.61e-06	2.35e-05	CcSEcCtD
Paroxetine—Dermatitis—Prednisone—hematologic cancer	7.6e-06	2.35e-05	CcSEcCtD
Paroxetine—Decreased appetite—Doxorubicin—hematologic cancer	7.59e-06	2.35e-05	CcSEcCtD
Paroxetine—Headache—Prednisone—hematologic cancer	7.56e-06	2.34e-05	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Doxorubicin—hematologic cancer	7.54e-06	2.33e-05	CcSEcCtD
Paroxetine—Fatigue—Doxorubicin—hematologic cancer	7.53e-06	2.33e-05	CcSEcCtD
Paroxetine—Urticaria—Epirubicin—hematologic cancer	7.5e-06	2.32e-05	CcSEcCtD
Paroxetine—Pain—Doxorubicin—hematologic cancer	7.47e-06	2.31e-05	CcSEcCtD
Paroxetine—Constipation—Doxorubicin—hematologic cancer	7.47e-06	2.31e-05	CcSEcCtD
Paroxetine—Abdominal pain—Epirubicin—hematologic cancer	7.46e-06	2.31e-05	CcSEcCtD
Paroxetine—Body temperature increased—Epirubicin—hematologic cancer	7.46e-06	2.31e-05	CcSEcCtD
Paroxetine—Hypersensitivity—Methotrexate—hematologic cancer	7.43e-06	2.3e-05	CcSEcCtD
Paroxetine—Asthenia—Methotrexate—hematologic cancer	7.24e-06	2.24e-05	CcSEcCtD
Paroxetine—Feeling abnormal—Doxorubicin—hematologic cancer	7.2e-06	2.23e-05	CcSEcCtD
Paroxetine—Nausea—Prednisone—hematologic cancer	7.17e-06	2.22e-05	CcSEcCtD
Paroxetine—Gastrointestinal pain—Doxorubicin—hematologic cancer	7.14e-06	2.21e-05	CcSEcCtD
Paroxetine—Pruritus—Methotrexate—hematologic cancer	7.14e-06	2.21e-05	CcSEcCtD
Paroxetine—Hypersensitivity—Epirubicin—hematologic cancer	6.95e-06	2.15e-05	CcSEcCtD
Paroxetine—Urticaria—Doxorubicin—hematologic cancer	6.94e-06	2.15e-05	CcSEcCtD
Paroxetine—Body temperature increased—Doxorubicin—hematologic cancer	6.9e-06	2.13e-05	CcSEcCtD
Paroxetine—Abdominal pain—Doxorubicin—hematologic cancer	6.9e-06	2.13e-05	CcSEcCtD
Paroxetine—Diarrhoea—Methotrexate—hematologic cancer	6.9e-06	2.13e-05	CcSEcCtD
Paroxetine—Asthenia—Epirubicin—hematologic cancer	6.77e-06	2.09e-05	CcSEcCtD
Paroxetine—Pruritus—Epirubicin—hematologic cancer	6.68e-06	2.06e-05	CcSEcCtD
Paroxetine—Dizziness—Methotrexate—hematologic cancer	6.67e-06	2.06e-05	CcSEcCtD
Paroxetine—Diarrhoea—Epirubicin—hematologic cancer	6.46e-06	2e-05	CcSEcCtD
Paroxetine—Hypersensitivity—Doxorubicin—hematologic cancer	6.43e-06	1.99e-05	CcSEcCtD
Paroxetine—Vomiting—Methotrexate—hematologic cancer	6.41e-06	1.98e-05	CcSEcCtD
Paroxetine—Rash—Methotrexate—hematologic cancer	6.36e-06	1.97e-05	CcSEcCtD
Paroxetine—Dermatitis—Methotrexate—hematologic cancer	6.35e-06	1.96e-05	CcSEcCtD
Paroxetine—Headache—Methotrexate—hematologic cancer	6.32e-06	1.95e-05	CcSEcCtD
Paroxetine—Asthenia—Doxorubicin—hematologic cancer	6.27e-06	1.94e-05	CcSEcCtD
Paroxetine—Dizziness—Epirubicin—hematologic cancer	6.24e-06	1.93e-05	CcSEcCtD
Paroxetine—Pruritus—Doxorubicin—hematologic cancer	6.18e-06	1.91e-05	CcSEcCtD
Paroxetine—Vomiting—Epirubicin—hematologic cancer	6e-06	1.86e-05	CcSEcCtD
Paroxetine—Nausea—Methotrexate—hematologic cancer	5.99e-06	1.85e-05	CcSEcCtD
Paroxetine—Diarrhoea—Doxorubicin—hematologic cancer	5.98e-06	1.85e-05	CcSEcCtD
Paroxetine—Rash—Epirubicin—hematologic cancer	5.95e-06	1.84e-05	CcSEcCtD
Paroxetine—Dermatitis—Epirubicin—hematologic cancer	5.95e-06	1.84e-05	CcSEcCtD
Paroxetine—Headache—Epirubicin—hematologic cancer	5.91e-06	1.83e-05	CcSEcCtD
Paroxetine—Dizziness—Doxorubicin—hematologic cancer	5.78e-06	1.79e-05	CcSEcCtD
Paroxetine—Nausea—Epirubicin—hematologic cancer	5.61e-06	1.73e-05	CcSEcCtD
Paroxetine—Vomiting—Doxorubicin—hematologic cancer	5.55e-06	1.72e-05	CcSEcCtD
Paroxetine—Rash—Doxorubicin—hematologic cancer	5.51e-06	1.7e-05	CcSEcCtD
Paroxetine—Dermatitis—Doxorubicin—hematologic cancer	5.5e-06	1.7e-05	CcSEcCtD
Paroxetine—Headache—Doxorubicin—hematologic cancer	5.47e-06	1.69e-05	CcSEcCtD
Paroxetine—Nausea—Doxorubicin—hematologic cancer	5.19e-06	1.6e-05	CcSEcCtD
Paroxetine—CHRM3—Signaling Pathways—BRAF—hematologic cancer	2.94e-06	3.14e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—EP300—hematologic cancer	2.94e-06	3.14e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CCL2—hematologic cancer	2.94e-06	3.14e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IL6R—hematologic cancer	2.93e-06	3.13e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CREBBP—hematologic cancer	2.92e-06	3.12e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CCL2—hematologic cancer	2.92e-06	3.12e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IL6R—hematologic cancer	2.91e-06	3.11e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CCL2—hematologic cancer	2.91e-06	3.11e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—BRAF—hematologic cancer	2.91e-06	3.11e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CREBBP—hematologic cancer	2.91e-06	3.11e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IL6R—hematologic cancer	2.9e-06	3.1e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CREBBP—hematologic cancer	2.9e-06	3.1e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MAPK8—hematologic cancer	2.89e-06	3.08e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CCL2—hematologic cancer	2.88e-06	3.08e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—AKT1—hematologic cancer	2.88e-06	3.07e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IL6R—hematologic cancer	2.88e-06	3.07e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CREBBP—hematologic cancer	2.87e-06	3.07e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PIK3CB—hematologic cancer	2.87e-06	3.06e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	2.86e-06	3.05e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—SRC—hematologic cancer	2.86e-06	3.05e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PIK3CD—hematologic cancer	2.83e-06	3.02e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—MTHFR—hematologic cancer	2.82e-06	3.02e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—EP300—hematologic cancer	2.81e-06	3e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—ALB—hematologic cancer	2.79e-06	2.98e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MAP2K1—hematologic cancer	2.79e-06	2.98e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—VEGFA—hematologic cancer	2.78e-06	2.97e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MAP2K1—hematologic cancer	2.78e-06	2.97e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PIK3CD—hematologic cancer	2.77e-06	2.96e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MAP2K1—hematologic cancer	2.77e-06	2.96e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PIK3CD—hematologic cancer	2.76e-06	2.95e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—STAT3—hematologic cancer	2.76e-06	2.94e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PIK3CD—hematologic cancer	2.75e-06	2.94e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—NRAS—hematologic cancer	2.75e-06	2.94e-05	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—PIK3CA—hematologic cancer	2.75e-06	2.93e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MAP2K1—hematologic cancer	2.74e-06	2.93e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—SRC—hematologic cancer	2.74e-06	2.92e-05	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—PIK3CA—hematologic cancer	2.73e-06	2.92e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PIK3CG—hematologic cancer	2.72e-06	2.91e-05	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—PIK3CA—hematologic cancer	2.72e-06	2.91e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PIK3CD—hematologic cancer	2.72e-06	2.91e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—KRAS—hematologic cancer	2.72e-06	2.9e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—KRAS—hematologic cancer	2.7e-06	2.88e-05	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—PIK3CA—hematologic cancer	2.7e-06	2.88e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—KRAS—hematologic cancer	2.69e-06	2.87e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PIK3R1—hematologic cancer	2.67e-06	2.85e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—KRAS—hematologic cancer	2.67e-06	2.85e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—VEGFA—hematologic cancer	2.67e-06	2.85e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—MTHFR—hematologic cancer	2.66e-06	2.84e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—FGF2—hematologic cancer	2.66e-06	2.84e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—FGF2—hematologic cancer	2.64e-06	2.82e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—MTHFR—hematologic cancer	2.64e-06	2.82e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—STAT3—hematologic cancer	2.64e-06	2.82e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MAPK3—hematologic cancer	2.63e-06	2.81e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—FGF2—hematologic cancer	2.63e-06	2.81e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—NRAS—hematologic cancer	2.63e-06	2.81e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PIK3R1—hematologic cancer	2.62e-06	2.8e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—FGF2—hematologic cancer	2.61e-06	2.78e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PIK3R1—hematologic cancer	2.6e-06	2.78e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PIK3R1—hematologic cancer	2.6e-06	2.77e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PIK3R1—hematologic cancer	2.57e-06	2.75e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MYC—hematologic cancer	2.56e-06	2.73e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TGFB1—hematologic cancer	2.55e-06	2.73e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—JAK2—hematologic cancer	2.55e-06	2.72e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—JAK2—hematologic cancer	2.53e-06	2.7e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CREBBP—hematologic cancer	2.53e-06	2.7e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—JAK2—hematologic cancer	2.52e-06	2.69e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MAPK3—hematologic cancer	2.52e-06	2.69e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—JAK2—hematologic cancer	2.5e-06	2.67e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—PIK3CA—hematologic cancer	2.49e-06	2.66e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MDM2—hematologic cancer	2.48e-06	2.65e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—PIK3CA—hematologic cancer	2.48e-06	2.65e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PTEN—hematologic cancer	2.48e-06	2.64e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—PIK3CA—hematologic cancer	2.47e-06	2.64e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MDM2—hematologic cancer	2.47e-06	2.64e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PIK3CB—hematologic cancer	2.47e-06	2.63e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MDM2—hematologic cancer	2.46e-06	2.63e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MYC—hematologic cancer	2.45e-06	2.62e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—PIK3CA—hematologic cancer	2.45e-06	2.62e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TGFB1—hematologic cancer	2.45e-06	2.61e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MDM2—hematologic cancer	2.44e-06	2.6e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PIK3CB—hematologic cancer	2.42e-06	2.58e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MTOR—hematologic cancer	2.42e-06	2.58e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MTOR—hematologic cancer	2.4e-06	2.57e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PIK3CB—hematologic cancer	2.4e-06	2.57e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PIK3CB—hematologic cancer	2.4e-06	2.56e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MTOR—hematologic cancer	2.4e-06	2.56e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PIK3CD—hematologic cancer	2.39e-06	2.56e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PIK3CG—hematologic cancer	2.37e-06	2.53e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MTOR—hematologic cancer	2.37e-06	2.53e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PIK3CB—hematologic cancer	2.37e-06	2.53e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—KRAS—hematologic cancer	2.37e-06	2.53e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—ALB—hematologic cancer	2.36e-06	2.52e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—EP300—hematologic cancer	2.36e-06	2.52e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	2.33e-06	2.48e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—HRAS—hematologic cancer	2.31e-06	2.46e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—HRAS—hematologic cancer	2.3e-06	2.45e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—HRAS—hematologic cancer	2.29e-06	2.44e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CDKN1B—hematologic cancer	2.27e-06	2.42e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—HRAS—hematologic cancer	2.27e-06	2.42e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—KRAS—hematologic cancer	2.27e-06	2.42e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PIK3R1—hematologic cancer	2.26e-06	2.42e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CDKN1B—hematologic cancer	2.26e-06	2.41e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CDKN1B—hematologic cancer	2.25e-06	2.4e-05	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—AKT1—hematologic cancer	2.24e-06	2.4e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PIK3CG—hematologic cancer	2.24e-06	2.39e-05	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—AKT1—hematologic cancer	2.23e-06	2.38e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CDKN1B—hematologic cancer	2.23e-06	2.38e-05	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—AKT1—hematologic cancer	2.22e-06	2.38e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CASP3—hematologic cancer	2.22e-06	2.37e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IL2—hematologic cancer	2.22e-06	2.37e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PIK3CG—hematologic cancer	2.22e-06	2.37e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CASP3—hematologic cancer	2.21e-06	2.36e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—IL6—hematologic cancer	2.21e-06	2.36e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IL2—hematologic cancer	2.21e-06	2.36e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CASP3—hematologic cancer	2.2e-06	2.35e-05	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—AKT1—hematologic cancer	2.2e-06	2.35e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IL2—hematologic cancer	2.2e-06	2.35e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CREBBP—hematologic cancer	2.2e-06	2.35e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—IL6—hematologic cancer	2.2e-06	2.35e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—IL6—hematologic cancer	2.19e-06	2.34e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CASP3—hematologic cancer	2.18e-06	2.33e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IL2—hematologic cancer	2.18e-06	2.33e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—PIK3CA—hematologic cancer	2.17e-06	2.32e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—IL6—hematologic cancer	2.17e-06	2.32e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CCND1—hematologic cancer	2.16e-06	2.31e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—JUN—hematologic cancer	2.16e-06	2.31e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CCND1—hematologic cancer	2.15e-06	2.3e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—JUN—hematologic cancer	2.15e-06	2.29e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CCND1—hematologic cancer	2.15e-06	2.29e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—JUN—hematologic cancer	2.14e-06	2.29e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PTEN—hematologic cancer	2.13e-06	2.28e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CCND1—hematologic cancer	2.12e-06	2.27e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—JUN—hematologic cancer	2.12e-06	2.26e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TP53—hematologic cancer	2.1e-06	2.25e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CDKN1A—hematologic cancer	2.09e-06	2.24e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PTEN—hematologic cancer	2.09e-06	2.23e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PIK3CB—hematologic cancer	2.09e-06	2.23e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PIK3CD—hematologic cancer	2.09e-06	2.23e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CDKN1A—hematologic cancer	2.08e-06	2.22e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—PIK3CA—hematologic cancer	2.08e-06	2.22e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PTEN—hematologic cancer	2.08e-06	2.22e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CDKN1A—hematologic cancer	2.08e-06	2.22e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CREBBP—hematologic cancer	2.07e-06	2.21e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PTEN—hematologic cancer	2.07e-06	2.21e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—ALB—hematologic cancer	2.06e-06	2.2e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CREBBP—hematologic cancer	2.06e-06	2.2e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CDKN1A—hematologic cancer	2.06e-06	2.2e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PTEN—hematologic cancer	2.05e-06	2.19e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MAPK8—hematologic cancer	2.04e-06	2.18e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—AKT1—hematologic cancer	2.04e-06	2.18e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MAPK8—hematologic cancer	2.03e-06	2.17e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—EP300—hematologic cancer	2.03e-06	2.17e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—AKT1—hematologic cancer	2.03e-06	2.16e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MAPK8—hematologic cancer	2.03e-06	2.16e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—AKT1—hematologic cancer	2.02e-06	2.16e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TP53—hematologic cancer	2.01e-06	2.15e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—HRAS—hematologic cancer	2.01e-06	2.15e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MAPK8—hematologic cancer	2.01e-06	2.14e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—AKT1—hematologic cancer	2e-06	2.14e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—EP300—hematologic cancer	1.99e-06	2.13e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—EP300—hematologic cancer	1.98e-06	2.12e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—EP300—hematologic cancer	1.97e-06	2.11e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PIK3R1—hematologic cancer	1.97e-06	2.1e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PIK3CD—hematologic cancer	1.97e-06	2.1e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—EP300—hematologic cancer	1.96e-06	2.09e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PIK3CD—hematologic cancer	1.95e-06	2.08e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ALB—hematologic cancer	1.94e-06	2.07e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—SRC—hematologic cancer	1.94e-06	2.07e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—SRC—hematologic cancer	1.93e-06	2.06e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—HRAS—hematologic cancer	1.93e-06	2.06e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IL6—hematologic cancer	1.92e-06	2.06e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ALB—hematologic cancer	1.92e-06	2.05e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—SRC—hematologic cancer	1.92e-06	2.05e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—SRC—hematologic cancer	1.9e-06	2.03e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—VEGFA—hematologic cancer	1.89e-06	2.01e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—VEGFA—hematologic cancer	1.88e-06	2e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—VEGFA—hematologic cancer	1.87e-06	2e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—STAT3—hematologic cancer	1.87e-06	1.99e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NRAS—hematologic cancer	1.86e-06	1.99e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—STAT3—hematologic cancer	1.86e-06	1.98e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PIK3R1—hematologic cancer	1.86e-06	1.98e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NRAS—hematologic cancer	1.85e-06	1.98e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—VEGFA—hematologic cancer	1.85e-06	1.98e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—STAT3—hematologic cancer	1.85e-06	1.98e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NRAS—hematologic cancer	1.85e-06	1.97e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IL6—hematologic cancer	1.84e-06	1.97e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PIK3R1—hematologic cancer	1.84e-06	1.97e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—STAT3—hematologic cancer	1.83e-06	1.96e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NRAS—hematologic cancer	1.83e-06	1.95e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PIK3CB—hematologic cancer	1.82e-06	1.94e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PTEN—hematologic cancer	1.8e-06	1.93e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MAPK3—hematologic cancer	1.78e-06	1.91e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—AKT1—hematologic cancer	1.78e-06	1.9e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MAPK3—hematologic cancer	1.78e-06	1.9e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MAPK3—hematologic cancer	1.77e-06	1.89e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MAPK3—hematologic cancer	1.75e-06	1.87e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PIK3CA—hematologic cancer	1.75e-06	1.87e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MYC—hematologic cancer	1.74e-06	1.85e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TGFB1—hematologic cancer	1.73e-06	1.85e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MYC—hematologic cancer	1.73e-06	1.84e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TGFB1—hematologic cancer	1.72e-06	1.84e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MYC—hematologic cancer	1.72e-06	1.84e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—EP300—hematologic cancer	1.72e-06	1.84e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TGFB1—hematologic cancer	1.72e-06	1.83e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PIK3CB—hematologic cancer	1.71e-06	1.83e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MYC—hematologic cancer	1.7e-06	1.82e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—AKT1—hematologic cancer	1.7e-06	1.82e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TGFB1—hematologic cancer	1.7e-06	1.82e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PIK3CB—hematologic cancer	1.7e-06	1.81e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—KRAS—hematologic cancer	1.6e-06	1.71e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—KRAS—hematologic cancer	1.6e-06	1.7e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—KRAS—hematologic cancer	1.59e-06	1.7e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—KRAS—hematologic cancer	1.57e-06	1.68e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PTEN—hematologic cancer	1.57e-06	1.68e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PIK3CA—hematologic cancer	1.5e-06	1.61e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—EP300—hematologic cancer	1.5e-06	1.6e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PTEN—hematologic cancer	1.48e-06	1.58e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PIK3CA—hematologic cancer	1.47e-06	1.57e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PTEN—hematologic cancer	1.47e-06	1.57e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PIK3CA—hematologic cancer	1.47e-06	1.57e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PIK3CA—hematologic cancer	1.46e-06	1.56e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PIK3CA—hematologic cancer	1.45e-06	1.55e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—AKT1—hematologic cancer	1.43e-06	1.52e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TP53—hematologic cancer	1.43e-06	1.52e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TP53—hematologic cancer	1.42e-06	1.51e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TP53—hematologic cancer	1.41e-06	1.51e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—EP300—hematologic cancer	1.41e-06	1.51e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—EP300—hematologic cancer	1.4e-06	1.5e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TP53—hematologic cancer	1.4e-06	1.49e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—HRAS—hematologic cancer	1.36e-06	1.46e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—HRAS—hematologic cancer	1.36e-06	1.45e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—HRAS—hematologic cancer	1.35e-06	1.44e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—HRAS—hematologic cancer	1.34e-06	1.43e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IL6—hematologic cancer	1.3e-06	1.39e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IL6—hematologic cancer	1.3e-06	1.39e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IL6—hematologic cancer	1.29e-06	1.38e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IL6—hematologic cancer	1.28e-06	1.37e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PIK3CA—hematologic cancer	1.27e-06	1.36e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—AKT1—hematologic cancer	1.23e-06	1.31e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—AKT1—hematologic cancer	1.2e-06	1.29e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—AKT1—hematologic cancer	1.2e-06	1.28e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—AKT1—hematologic cancer	1.19e-06	1.27e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—AKT1—hematologic cancer	1.18e-06	1.26e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PIK3CA—hematologic cancer	1.11e-06	1.18e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PIK3CA—hematologic cancer	1.04e-06	1.12e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—AKT1—hematologic cancer	1.04e-06	1.11e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PIK3CA—hematologic cancer	1.04e-06	1.11e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—AKT1—hematologic cancer	9.06e-07	9.67e-06	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—AKT1—hematologic cancer	8.53e-07	9.11e-06	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—AKT1—hematologic cancer	8.46e-07	9.04e-06	CbGpPWpGaD
